Welcome to our dedicated page for Oncology Institute SEC filings (Ticker: TOI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oncology Institute's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oncology Institute's regulatory disclosures and financial reporting.
The Oncology Institute, Inc. reported total revenue of $147.4 million for the three months ended March 31, 2026, up from $104.4 million a year earlier, driven mainly by growth in specialty pharmacy and patient services.
The company posted a net loss of $2.5 million, a significant improvement from a $19.6 million loss in the prior-year quarter, with net loss per share narrowing to $0.02 from $0.21. Operating cash outflow was $2.2 million, and cash and cash equivalents were $30.3 million as of March 31, 2026. Long-term debt, primarily a senior secured convertible note, stood at $78.6 million net, while stockholders’ deficit was $16.3 million.
Management evaluated liquidity and, despite the accumulated deficit of $273.9 million, concluded the company has sufficient resources to fund operations for at least one year from issuance of these financial statements.
The Oncology Institute, Inc. has called a virtual annual stockholder meeting for June 17, 2026 at 11:00 a.m. Pacific Time, accessible via webcast at www.proxydocs.com/TOI. Stockholders of record as of April 24, 2026, representing 99,982,933 common shares, may vote.
Investors are being asked to elect eight directors, ratify BDO USA, P.C. as independent auditor for the year ending December 31, 2026, approve on an advisory basis executive compensation, and select the preferred frequency of future say-on-pay votes, with the Board recommending annual votes. The Board highlights a majority of independent directors, separated Chair and CEO roles, and standard board committees overseeing audit, compensation, governance and healthcare compliance. The proxy also details 2025 executive pay packages combining salary, performance-based cash bonuses tied to revenue, gross profit and Adjusted EBITDA, and time-vested equity awards.
Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.
Oncology Institute, Inc. director Mohit Kaushal reported open-market sales of 95,719 shares of Common Stock. He sold 57,286 shares on April 14, 2026 at a volume-weighted average price of $3.5017 per share and 38,433 shares on April 16, 2026 at a volume-weighted average price of $3.5005 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the reported sales, Kaushal directly holds 172,583 shares of Oncology Institute common stock.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of common stock. On April 9, 2026, Chernett bought 20,000 shares at $3.10 per share. After this purchase, Chernett directly owned 10,499,358 common shares.
Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.
The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.
England Kristin reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Administrative Officer Kristin England received a grant of 55,743 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. Following this award, she directly holds 153,780 shares of the company’s common stock.
The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting commencement date and the remaining three quarters vesting in equal annual installments on each of the next three anniversaries, subject to her continued service with the company.